CalciMedica (CALC) Appoints Stephen Bardin as CFO

CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Stephen Bardin as Chief Financial Officer and the planned departure of Daniel Geffken, Interim Chief Financial Officer upon filing the Company's third quarter financial statements. Mr. Bardin brings extensive capital raising, corporate development, and strategic finance expertise to CalciMedica, having most recently served as CFO of atai Life Sciences.

"We are delighted to bring Stephen on board. He is a skilled and experienced biotechnology executive who will be invaluable to CalciMedica as we advance our clinical-stage pipeline," said Rachel Leheny Ph.D., Chief Executive Officer of CalciMedica. "Stephen has been advising us on various strategic matters for several months and, most recently, was critical in executing our successful public financing last week. We look forward to his many future contributions as he now joins us full-time."

"CalciMedica has made impressive recent progress, delivering compelling clinical data for large and underserved patient populations," said Mr. Bardin. "The CARPO Phase 2b data in patients with acute pancreatitis announced last month is promising and provides an optimistic readthrough to KOURAGE, CalciMedica's Phase 2 trial in acute kidney injury, which is expected to read out next year. I look forward to working more closely with the team as we advance AKI in the clinic and prepare for a Phase 3 program in AP."

Mr. Bardin most recently served as CFO of atai Life Sciences where he played a key role in the company's investor relations, business development, capital allocation, and financial operations activities. Prior to that, Mr. Bardin spent nearly three years at BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company with a broad pipeline of development programs, where he oversaw a broad range of finance activities and helped raise over $2B through a variety of financing transactions. Prior to that, Mr. Bardin held positions focused on finance, operations, and corporate development at Myovant Sciences, Inc., a subsidiary of Roivant at the time. He began his career advising life sciences companies at the Boston Consulting Group. Mr. Bardin holds an M.B.A. from the Stanford Graduate School of Business and graduated summa cum laude from Duke University with a B.S.E. in Biomedical Engineering.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• Arcosa stockholders approve $150-per-share cash buyout by CRH